Form 4: Alnylam Pharmaceuticals CEO Yvonne Greenstreet Reports Gift Transfer and 401(k) Stock Acquisition

CEO Yvonne Greenstreet reports a gift transfer of Alnylam Pharmaceuticals stock for estate planning and acquisition of shares through the company's 401(k) plan.

Summary

• Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, reported a transaction on May 2, 2025.
• The transaction involved a gift of 41,311 shares of common stock to the Yvonne Greenstreet 2024 Irrevocable Trust Dtd 10/29/2024 for estate planning purposes.
• Greenstreet is neither the trustee nor a beneficiary of this trust.
• Additionally, Greenstreet acquired 407 shares of ALNY common stock through the issuer's 401(k) plan as a result of the company's matching contribution program.
• Following these transactions, Greenstreet directly owns 57,324 shares and indirectly owns 407 shares through a managed account.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and do not indicate a strong positive or negative outlook. The 401k purchase is slightly positive.

Positives

• The acquisition of shares through the 401(k) plan indicates confidence in the company's future.
• The reported transactions do not suggest any negative sentiment from the CEO regarding the company's prospects.

Industry Context

Executive stock transactions are common and closely monitored as indicators of management's confidence in the company's performance and future prospects. Gifts for estate planning are a normal part of wealth management.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• The gift transfer is a personal matter for the CEO.
• The 401(k) stock acquisition is a standard employee benefit.

Key Dates

Keywords

Alnylam Pharmaceuticals, Yvonne Greenstreet, CEO, Form 4, Beneficial Ownership, Stock, Gift, 401(k), Estate Planning